The Developmental Process of MK-3475 in Melanoma

Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the development process of PD-1 antibody MK-3475 in melanoma.

Clinical Pearls

• MK-3475 has gone through phase I testing
• Physicians are eagerly awaiting data from a phase II clinical trial comparing chemotherapy to MK-3475 in patients who have previously received ipilimumab
• A trial studying two dosing regimens of MK-3475 compared to ipilimumab in frontline therapy for patients with metastatic melanoma is currently accruing
• MK-3475 is also being developed in other cancers, such as lung, bladder, and head and neck